Rich Pharmaceuticals (RCHA) 10-Q 19 Feb 14 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Dec. 31, 2013	Feb. 18, 2014
Document And Entity Information	'	'
Entity Registrant Name	'Rich Pharmaceuticals, Inc.	'
Entity Central Index Key	'0001504389	'
Document Type	'10-Q	'
Document Period End Date	31-Dec-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--03-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	414,328,104
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013	Mar. 31, 2013
Current Assets	'	'
Cash	$17,565	$1,588
Total Current Assets	17,565	1,588
Fixed assets, net of accumulated depreciation (Note 4)	1,380	'
Other Assets	'	'
Intangible assets, net of accumulated amortization of $nil (Note 5)	28,613	'
Total Other Assets	28,613	'
Total assets	47,558	1,588
Current Liabilities	'	'
Accounts payable and accrued expenses	66,285	6,700
Due to related parties (Note 6)	100	24,318
Loans payable (Note 7)	147,050	'
Total Current Liabilities	213,435	31,018
STOCKHOLDERS DEFICIT	'	'
Preferred Stock, $0.001 par value, 10,000,000 shares authorized, 6,000,000 and nil shares issued and outstanding, respectively (Note 8)	6,000	'
Common Stock, $0.001 par value, 37,503,000,000 shares authorized, 414,328,104 and 1,093,837,500 shares issued and outstanding, respectively (Note 8)	414,328	1,093,837
Additional Paid-in Capital	-197,393	-1,041,337
Additional Paid-in Capital - Stock warrants	14,582	'
Deficit Accumulated During the Development Stage	-403,394	-81,930
Total Stockholders' Deficit	-165,877	-29,430
Total Liabilities and Stockholders Deficit	$47,558	$1,588

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Statement of Financial Position [Abstract]	'	'
Common Stock, Par Value	$0.00	$0.00
Common Stock, Shares Authorized	37,503,000,000	37,503,000,000
Common Stock, Issued	414,328,104	1,093,837,500
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Issued	6,000,000	0
Accumulated Amortization of intangible assets	'	'

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended		9 Months Ended		41 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Income Statement [Abstract]	'	'	'	'	'
Revenue	'	'	'	'	'
Operating Expenses	'	'	'	'	'
Consulting - related party	79,856	'	148,606	'	148,606
Consulting	'	'	700	'	700
Office	17,008	'	20,343	'	20,343
Depreciation	39	'	39	'	39
Payroll & fees	15,736	'	15,736	'	15,736
Professional fees	22,035	2,000	85,608	4,000	167,538
Regulatory fees	936	'	35,856	'	35,856
Travel	8,318	'	14,576	'	14,576
Total Operating Expenses	143,928	2,000	321,464	4,000	403,394
Net Loss	($143,928)	($2,000)	($321,464)	($4,000)	($403,394)
Net Loss Per Share - Basic and Diluted	'	'	'	'	'
Weighted Average Shares Outstanding - Basic and Diluted	414,053,647	1,093,837,500	680,429,772	1,093,837,500	'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	9 Months Ended		41 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Operating Activities	'	'	'
Net loss	($321,464)	($4,000)	($403,394)
Depreciation	39	'	39
Changes in operating assets and liabilities:	'	'	'
Decrease in prepaid expenses	'	4,000	'
Increase in accounts payable	59,584	'	66,285
Net Cash Used in Operating Activities	-261,841	'	-337,070
Investing Activities	'	'	'
Acquisition of fixed assets	-1,419	-1,419	'
Acquisition of intangible assets	-22,413	'	-22,413
Net Cash Used in Investing Activities	-23,832	'	-23,832
Financing Activities	'	'	'
Proceeds from loans payable	147,050	'	147,050
Proceeds from note payable - related party	4,600	'	28,917
Proceeds from sale of common stock	150,000	'	202,500
Net Cash Provided by Financing Activities	301,650	'	378,467
Increase in Cash	15,977	'	17,565
Cash - Beginning of Period	1,588	29,811	'
Cash - End of Period	17,565	29,811	17,565
Non-cash Financing and Investing Activities:	'	'	'
Acquisition of intangibles for common and preferred shares	6,200	'	6,200
Supplemental Disclosures:	'	'	'
Interest paid	'	'	'
Income taxes paid	'	'	'

Nature_of_Operations

Nature of Operations	9 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of Operations	'
	On August 9, 2010 we were incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, we were in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia.
	On July 18, 2013, we designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class.
	On July 18, 2013, we entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property we issued 198,625 pre-split common shares, and 6,000,000 Series “A” Preferred Stock. The common and preferred shares were valued at a nominal amount of $199 and $6,000, respectively. We further agreed to use our best efforts to complete a financing resulting in proceeds of at least $2,000,000. If we are unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. As part of the Assignment Agreement, Imagic LLC and its principals have the option prior to November 1, 2014, to assign to us any and all interest they have in the patents and intellectual property related to Hodgkin’s Lymphoma in consideration for us issuing 476,820 pre-split common shares and 1.0408 pre-split common shares for each common share issued prior to receiving notice of intent to exercise the option.
	On July 19, 2013, we entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, we transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. As a result of this Sale Agreement, we are no longer pursuing our boiler business. In consequence to the Sale Agreement two former officers sold 1,275,000 pre-split common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 1,200,517 of those shares he received and returned them to treasury. Certain other shareholders also agreed to cancel 630,000 pre-split common shares.
	On August 26, 2013, as a consequence of our new business direction, we changed our name to Rich Pharmaceuticals, Inc.
	On September 5, 2013, we increased our authorized common shares, par value $0.001, from 90,000,000 shares to 37,503,000,000 shares. Correspondingly, we affirmed a forward split of 416.7 for 1 in which each shareholder was issued 416.7 common shares for each share held. Prior to approval of the forward split, we had a total of 993,108 issued pre-split common shares and, effective October 2, 2013; we had 413,828,104 issued post-split common shares.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Basis of Presentation
	The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”), and should be read in conjunction with our audited financial statements and notes thereto contained in our Annual Report filed with the SEC on Form 10-K. In our opinion, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for our interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosure contained in the audited financial statements for fiscal 2013, as reported in the Form 10-K, have been omitted.
	Use of Estimates
	The preparation of financial statements in accordance with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. We regularly evaluate estimates and assumptions related to the useful life and recoverability of long-lived assets and deferred income tax asset valuation allowances. We base our estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by us may differ materially and adversely from our estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
	Fixed Assets
	Property and equipment are recorded at cost and are depreciated using principally the straight-line method over the estimated useful lives of the related assets. The average useful lives of fixed assets are as follows
	Computer equipment 3 years
	Long-Lived Assets
	We account for our long-lived assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. We assess recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value. As of December 31, 2013 we did not have any Long-Lived Assets that were impaired.
	Recently Issued Accounting Pronouncements
	We do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow.

Going_Concern

Going Concern	9 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Going Concern	'
	The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have begun operations but have not generated revenue to date. These conditions give rise to doubt about our ability to continue as a going concern. These financial statements do not include adjustments relating to the recoverability and classification of reported asset amounts or the amount and classification of liabilities that might be necessary should we be unable to continue as a going concern. Our continuation as a going concern is dependent upon our ability to obtain additional financing and to generate profits and positive cash flow. We will require additional cash of $2,000,000 over the next twelve months to cover the costs of overhead and operations, drug manufacturing, maintaining our patent portfolio, and conducting clinical trials for the indication Acute Myeloid Leukemia (“AML”).We plan to raise the required capital pursuant to a private equity financing in the near term, but there is no guarantee or assurances that we will be able to do so.

Fixed_Assets

Fixed Assets	9 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Fixed Assets	'
	Fixed Assets consist of the following:
		31-Dec-13			31-Mar-13
	Computer Equipment	$	1,419		$	—
	Less accumulated depreciation		(39	)		—
		$	1,380		$	—

Intangible_Assets

Intangible Assets	9 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets	'
	On July 18, 2013, we entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property we issued 198,625 pre-split common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a nominal value of $199 and $6,000, respectively.

Related_Party_Debt_and_Transac

Related Party Debt and Transactions	9 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Debt and Transactions	'
	On July 19, 2013, we entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, we transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. As a result of this Sale Agreement, we are no longer pursuing our boiler business. In consequence to the Sale Agreement two former officers sold 1,275,000 pre-split common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 1,200,517 of those shares he received and returned them to treasury.
	We received a loan of $100 from our new officer/director to open a bank account.
	On September 6, 2013, we entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years; annual compensation of $275,000; an amount equal to 3 months compensation payable upon entering into the agreement; and options to purchase up to 3,000,000 shares of common stock at an exercise price of $0.02 per post-split share; 50% of which are vested on October 1, 2013, and 50% of which will vest monthly over 24 months of continued employment.

Notes_Payable

Notes Payable	9 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Notes Payable	'
	Unrelated third parties loaned us $147,050 during the nine months ended September 30, 2013 to help us expand our operations. These loans are unsecured and non-interest bearing.

Common_and_Preferred_Shares

Common and Preferred Shares	9 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Common and Preferred Shares	'
	On July 18, 2013, we designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and vote with common shares as a single class.
	On July 18, 2013, we entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property we issued 198,625 pre-split common shares, and 6,000,000 Series “A” Preferred Stock. The common and preferred shares were valued at a nominal amount of $199 and $6,000, respectively. As part of the Assignment Agreement, Imagic LLC and its principals have the option prior to November 1, 2014, to assign to us any and all interest they have in the patents and intellectual property related to Hodgkin’s Lymphoma in consideration for us issuing 476,820 pre-split common shares and 1.0408 pre-split common shares for each common share issued prior to receiving notice of intent to exercise the option.
	On July 19, 2013, we entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. In consequence to the Sale Agreement two former officers sold 1,275,000 pre-split common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 1,200,517 of those shares he received and returned them to treasury. Certain other shareholders also agreed to cancel 630,000 pre-split common shares.
	On September 5, 2013, we increased our authorized common shares, par value $0.001, from 90,000,000 shares to 37,503,000,000 shares. Correspondingly, we affirmed a forward split of 416.7 for 1 in which each shareholder was issued 416.7 common shares for each share held. Prior to approval of the forward split, we had a total of 993,108 issued pre-split common shares and, effective October 2, 2013; we had 413,828,104 issued post-split common shares.
	On September 6, 2013, we approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid us in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 60,000,000 post-split common shares have been reserved for awards under the 2013 Plan. On September 6, 2013, we approved the grant of 41,000,000 options to purchase post-split common stock to a total of eight directors, officers, employees and consultants of our Company. The options have an exercise price of $0.02 per post-split common share and are subject to vesting schedules and other terms as provided in the individual option grants. The first tranche vested on October 1, 2013.
	On October 29, 2013, we issued 250,000 shares of Company common stock at Thirty Cents ($.30) per share, and warrants to purchase 250,000 shares of Company common stock at Fifty Cents ($.50) per share for a one year term. The value of the warrants at December 31, 2013 was $7,291.
	On December 11, 2013, we issued 250,000 shares of Company common stock at Thirty Cents ($.30) per share, and warrants to purchase 250,000 shares of Company common stock at Fifty Cents ($.50) per share for a one year term. The value of the warrants at December 31, 2013 was $7,291.

Stock_Warrants

Stock Warrants	9 Months Ended
	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]	'
Stock Warrants	'
	The Company issued 500,000 stock warrants in connection with the issuance of common stock during the quarter ended December 31, 2013. The Company has accounted for these warrants as equity instruments in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock, and as such, will be classified in stockholders’ equity as they meet the definition of “…indexed to the issuer’s stock” in ASC 815-40. The Company has estimated the fair value of the warrants issued in connection with the private placement at $0.03/warrant as of the grant dates using the Black-Scholes option pricing model. Each common stock purchase warrant has an exercise price of $0.50 and will expire 12 months from the effective date of the S-1.

Subsequent_Events

Subsequent Events	9 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC (see Note 5) is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division. The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang. The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper.
	The Company believes the allegations in the complaint are without merit and the Company intends to defend itself in the litigation. However, we may incur substantial expenses and the diversion of financial resources and management personnel in responding to the complaint. Additionally, an adverse determination against us in the litigation may subject us to significant liabilities or require us to seek licenses that may not be available from third parties on commercially favorable terms, if at all. Further, an adverse determination against us in the litigation may require us to pay substantial financial damages, which can be tripled if the infringement is deemed willful, or be required to discontinue or significantly delay development, marketing, selling and licensing of the Company’s affected products and intellectual property rights.
	We have evaluated all subsequent events through the date these financial statements were issued and determined that there are no additional subsequent events to record or to disclose.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”), and should be read in conjunction with our audited financial statements and notes thereto contained in our Annual Report filed with the SEC on Form 10-K. In our opinion, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for our interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosure contained in the audited financial statements for fiscal 2013, as reported in the Form 10-K, have been omitted.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in accordance with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. We regularly evaluate estimates and assumptions related to the useful life and recoverability of long-lived assets and deferred income tax asset valuation allowances. We base our estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by us may differ materially and adversely from our estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Fixed Assets	'
	Fixed Assets consist of the following:
		31-Dec-13			31-Mar-13
	Computer Equipment	$	1,419		$	—
	Less accumulated depreciation		(39	)		—
		$	1,380		$	—
Long-Lived Assets	'
	Long-Lived Assets
	We account for our long-lived assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. We assess recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value. As of December 31, 2013 we did not have any Long-Lived Assets that were impaired.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	We do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow.

Fixed_Assets_Tables

Fixed Assets (Tables)	9 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Fixed Assets	'
		31-Dec-13			31-Mar-13
	Computer Equipment	$	1,419		$	—
	Less accumulated depreciation		(39	)		—
		$	1,380		$	—

Nature_of_Operations_Details_N

Nature of Operations (Details Narrative) (USD $)	9 Months Ended
	Dec. 31, 2013	Dec. 11, 2013	Oct. 29, 2013	Sep. 30, 2013	Sep. 05, 2013	Jun. 30, 2013	Mar. 31, 2013
Date Of Incorporation	9-Aug-10	'	'	'	'	'	'
Cash Equivalents	$17,565	'	'	'	'	'	$1,588
Common Stock, shares issued	198,625	'	'	'	'	'	'
Series A Preferred Stock, shares issued	6,000,000	'	'	'	'	'	'
Common stock, value	199	'	'	'	'	'	'
Series A Preferred Stock, value	6,000	'	'	'	'	'	'
Additional cash required	2,000,000	'	'	'	'	'	'
Common Stock, Shares Authorized	37,503,000,000	'	'	37,503,000,000	90,000,000	37,503,000,000	37,503,000,000
Common Stock, Par Value	$0.00	'	'	$0.00	$0.00	$0.00	$0.00
Stock split ratio	'	'	'	'	'416.7:1	'	'
Common Stock, Issued	414,328,104	250,000	250,000	413,828,104	993,108	1,093,837,500	1,093,837,500
Asset Assign Agmt	'	'	'	'	'	'	'
Date of Agreement	18-Jul-13	'	'	'	'	'	'
Common Stock, shares issued	198,625	'	'	'	'	'	'
Series A Preferred Stock, shares issued	6,000,000	'	'	'	'	'	'
Common stock, value	199	'	'	'	'	'	'
Series A Preferred Stock, value	6,000	'	'	'	'	'	'
Sale Agmt	'	'	'	'	'	'	'
Date of Agreement	19-Jul-13	'	'	'	'	'	'
Cancellation of loans	$28,818	'	'	'	'	'	'
Shares sold by former officers	1,275,000	'	'	'	'	'	'
Shares returned to treasury	1,200,517	'	'	'	'	'	'

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details Narrative)	9 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Computer equipment	'3 years

Going_Concern_Details_Narrativ

Going Concern (Details Narrative) (USD $)	9 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Additional cash required	$2,000,000

Fixed_Assets_Schedule_of_Fixed

Fixed Assets - Schedule of Fixed Assets (Details) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Accounting Policies [Abstract]	'	'
Computer Equipment	$1,419	'
Less accumulated depreciation	-39	'
Total	$1,380	'

Intangible_Assets_Details_Narr

Intangible Assets (Details Narrative) (USD $)	9 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Common Stock, shares issued	198,625
Series A Preferred Stock, shares issued	6,000,000
Common stock, value	$199
Series A Preferred Stock, value	$6,000

Related_Party_Debt_and_Transac1

Related Party Debt and Transactions (Details Narrative) (USD $)	9 Months Ended
	Dec. 31, 2013
Loan from related party	$100
Sale Agmt	'
Date of Agreement	19-Jul-13
Cancellation of loans	28,818
Shares sold by former officers	1,275,000
Shares returned to treasury	1,200,517
Employment Agmt	'
Term of Agreement	'2 years
Annual Compensation	$275,000
Options to purchase	3,000,000
Options to purchase, exercise price	$0.02

Notes_Payable_Details_Narrativ

Notes Payable (Details Narrative) (USD $)	9 Months Ended		41 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Debt Disclosure [Abstract]	'	'	'
Proceeds from loans payable	$147,050	'	$147,050

Common_and_Preferred_Shares_De

Common and Preferred Shares (Details Narrative) (USD $)	9 Months Ended	41 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 11, 2013	Oct. 29, 2013	Sep. 30, 2013	Sep. 06, 2013	Sep. 05, 2013	Jun. 30, 2013	Mar. 31, 2013
Common Stock, Shares Authorized	37,503,000,000	37,503,000,000	'	'	37,503,000,000	'	90,000,000	37,503,000,000	37,503,000,000
Common Stock, Par Value	$0.00	$0.00	'	'	$0.00	'	$0.00	$0.00	$0.00
Preferred Stock, Shares Authorized	10,000,000	10,000,000	'	'	10,000,000	'	'	10,000,000	10,000,000
Preferred Stock, Par Value	$0.00	$0.00	'	'	$0.00	'	'	$0.00	$0.00
Issuance of common stock for cash, shares	'	2,625,000	'	'	'	'	'	'	'
Issuance of common stock for cash, par value per share	'	0.02	'	'	'	'	'	'	'
Issuance of common stock for cash, amount	'	$52,500	'	'	'	'	'	'	'
Common Stock, Issued	414,328,104	414,328,104	250,000	250,000	413,828,104	'	993,108	1,093,837,500	1,093,837,500
Preferred Stock, Issued	6,000,000	6,000,000	'	'	6,000,000	'	'	0	0
Common Stock, shares issued	198,625	'	'	'	'	'	'	'	'
Series A Preferred Stock, shares issued	6,000,000	'	'	'	'	'	'	'	'
Common stock, value	199	'	'	'	'	'	'	'	'
Series A Preferred Stock, value	6,000	'	'	'	'	'	'	'	'
Stock split ratio	'	'	'	'	'	'	'416.7:1	'	'
Common Stock, post split	'	'	'	'	'	60,000,000	'	'	'
Common Stock, options	'	'	'	'	'	41,000,000	'	'	'
Common Stock, exercise price	'	'	$0.30	$0.30	'	$0.02	'	'	'
Issuance of warrants, shares	'	'	250,000	250,000	'	'	'	'	'
Issuance of warrants, per share	$0.50	$0.50	$0.50	$0.50	'	'	'	'	'
Issuance of warrants, value	'	'	7,291	7,291	'	'	'	'	'
Sale Agmt	'	'	'	'	'	'	'	'	'
Cancellation of loans	28,818	'	'	'	'	'	'	'	'
Shares sold by former officers	1,275,000	'	'	'	'	'	'	'	'
Shares returned to treasury	1,200,517	'	'	'	'	'	'	'	'
Date of Agreement	19-Jul-13	'	'	'	'	'	'	'	'
Asset Assign Agmt	'	'	'	'	'	'	'	'	'
Date of Agreement	18-Jul-13	'	'	'	'	'	'	'	'
Common Stock, shares issued	198,625	'	'	'	'	'	'	'	'
Series A Preferred Stock, shares issued	6,000,000	'	'	'	'	'	'	'	'
Common stock, value	199	'	'	'	'	'	'	'	'
Series A Preferred Stock, value	$6,000	'	'	'	'	'	'	'	'

Stock_Warrants_Details_Narrati

Stock Warrants (Details Narrative) (USD $)	9 Months Ended
	Dec. 31, 2013	Dec. 11, 2013	Oct. 29, 2013
Other Liabilities Disclosure [Abstract]	'	'	'
Issuance of warrants, shares	500,000	'	'
Issuance of warrants private placement, per share	$0.03	'	'
Issuance of warrants, per share	$0.50	$0.50	$0.50